635 related articles for article (PubMed ID: 31853000)
1. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
2. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
Liu X; Hoft DF; Peng G
J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
[TBL] [Abstract][Full Text] [Related]
3. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
4. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.
Crespo J; Sun H; Welling TH; Tian Z; Zou W
Curr Opin Immunol; 2013 Apr; 25(2):214-21. PubMed ID: 23298609
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
6. Counteracting CAR T cell dysfunction.
Poorebrahim M; Melief J; Pico de Coaña Y; L Wickström S; Cid-Arregui A; Kiessling R
Oncogene; 2021 Jan; 40(2):421-435. PubMed ID: 33168929
[TBL] [Abstract][Full Text] [Related]
7. Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms.
Davoodzadeh Gholami M; Kardar GA; Saeedi Y; Heydari S; Garssen J; Falak R
Cell Immunol; 2017 Dec; 322():1-14. PubMed ID: 29079339
[TBL] [Abstract][Full Text] [Related]
8. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
9. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
10. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
van Pul KM; Fransen MF; van de Ven R; de Gruijl TD
Front Immunol; 2021; 12():643291. PubMed ID: 33732264
[TBL] [Abstract][Full Text] [Related]
12. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
13. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells.
Xie Y; Xie F; Zhang L; Zhou X; Huang J; Wang F; Jin J; Zhang L; Zeng L; Zhou F
Adv Sci (Weinh); 2021 Nov; 8(22):e2101672. PubMed ID: 34658167
[TBL] [Abstract][Full Text] [Related]
14. Vascular Microenvironment, Tumor Immunity and Immunotherapy.
Lamplugh Z; Fan Y
Front Immunol; 2021; 12():811485. PubMed ID: 34987525
[TBL] [Abstract][Full Text] [Related]
15. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.
Ye J; Ma C; Hsueh EC; Dou J; Mo W; Liu S; Han B; Huang Y; Zhang Y; Varvares MA; Hoft DF; Peng G
EMBO Mol Med; 2014 Oct; 6(10):1294-311. PubMed ID: 25231413
[TBL] [Abstract][Full Text] [Related]
16. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
17. Senescent T cells: a potential biomarker and target for cancer therapy.
Zhang J; He T; Xue L; Guo H
EBioMedicine; 2021 Jun; 68():103409. PubMed ID: 34049248
[TBL] [Abstract][Full Text] [Related]
18. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
Dhodapkar MV; Dhodapkar KM
Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
[TBL] [Abstract][Full Text] [Related]
19. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
20. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
Front Immunol; 2021; 12():645242. PubMed ID: 33815400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
